Citigroup Inc. reiterated their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research note released on Thursday morning, MarketBeat Ratings reports. Citigroup Inc. currently has a $156.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $114.00.

PBYI has been the subject of a number of other reports. J P Morgan Chase & Co restated a buy rating and issued a $131.00 target price on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Leerink Swann restated an outperform rating and issued a $125.00 target price on shares of Puma Biotechnology in a research report on Wednesday, August 2nd. Bank of America Corporation reiterated a buy rating and set a $117.00 price objective (up previously from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. BidaskClub upgraded Puma Biotechnology from a buy rating to a strong-buy rating in a research report on Monday, July 31st. Finally, Royal Bank Of Canada set a $88.00 price objective on Puma Biotechnology and gave the company a hold rating in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Puma Biotechnology presently has an average rating of Buy and an average target price of $122.89.

Shares of Puma Biotechnology (PBYI) opened at 121.40 on Thursday. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $127.02. The stock has a 50 day moving average price of $101.83 and a 200 day moving average price of $73.87. The firm’s market capitalization is $4.52 billion.

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.78). Analysts predict that Puma Biotechnology will post ($8.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/09/citigroup-inc-reiterates-buy-rating-for-puma-biotechnology-inc-pbyi.html.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now directly owns 42,239 shares of the company’s stock, valued at $5,068,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the transaction, the insider now directly owns 4,170,623 shares in the company, valued at $395,083,116.79. The disclosure for this sale can be found here. Insiders sold 45,173 shares of company stock worth $4,738,189 over the last ninety days. 22.70% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new position in Puma Biotechnology during the second quarter worth $122,000. Cubist Systematic Strategies LLC acquired a new position in Puma Biotechnology during the second quarter worth $146,000. Kazazian Asset Management LLC acquired a new position in Puma Biotechnology during the second quarter worth $209,000. Teacher Retirement System of Texas acquired a new position in Puma Biotechnology during the second quarter worth $211,000. Finally, Ameritas Investment Partners Inc. increased its position in Puma Biotechnology by 5.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 140 shares during the last quarter. 80.98% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.